Bicycle Therapeutics(US:BCYC)2022-03-20 09:56Company Overview - Bicycle Therapeutics is pioneering Bicycles, a novel class of innovative medicines[4] - The company has a cash balance of $438.7 million as of December 31, 2021, which is expected to fund operations into 2024[5,6] - The company has a strong intellectual property portfolio with 122 patent families as of December 31, 2021[5,9] - The company has approximately 119 employees located in Cambridge, UK and Lexington, MA[5] Technology Platform - Bicycles combine the advantages of both small molecules (1.5-2kDa) and antibodies (>150kDa) offering high specificity and complex protein target druggability[10,11] - The Bicycle platform delivers a toolkit of building blocks to create novel medicines, including Monomeric Bicycles, Targeted Drug Conjugates, and Tumor-Targeted immune cell agonists[12,15] - Bicycle Toxin Conjugates (BTCs) preclinical data indicates higher potency and specificity with fewer side effects than Antibody-Drug Conjugates (ADCs)[26] Clinical Programs - BT5528 (EphA2): Phase I dose escalation trial showed preliminary anti-tumor activity in ovarian cancer (1 PR out of 8 patients) and urothelial cancer (2 PRs out of 2 patients)[5,69,70,71] - BT8009 (Nectin-4): Phase I dose escalation trial showed preliminary responses in urothelial cancer patients, with 4 out of 11 patients achieving a partial response (PR)[5,88,91,101] - BT7480 (Nectin-4/CD137): A Bicycle TICA that entered Phase I clinical trials in Q4 2021[5,58,113]